Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:JNJ
  • CUSIP: 47816010
  • Web:
  • Market Cap: $360.49 billion
  • Outstanding Shares: 2,693,833,000
Average Prices:
  • 50 Day Moving Avg: $128.09
  • 200 Day Moving Avg: $121.63
  • 52 Week Range: $109.32 - $136.20
  • Trailing P/E Ratio: 22.49
  • Foreward P/E Ratio: 17.47
  • P/E Growth: 2.95
Sales & Book Value:
  • Annual Revenue: $72.17 billion
  • Price / Sales: 4.99
  • Book Value: $26.10 per share
  • Price / Book: 5.13
  • Annual Dividend: $3.36
  • Dividend Yield: 2.5%
  • EBIDTA: $25.12 billion
  • Net Margins: 22.87%
  • Return on Equity: 26.50%
  • Return on Assets: 13.38%
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 2.52%
  • Quick Ratio: 2.17%
  • Average Volume: 5.78 million shs.
  • Beta: 0.81
  • Short Ratio: 3.12

Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Tuesday, May 30th will be paid a dividend of $0.84 per share on Tuesday, June 13th. This represents a $3.36 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date is Thursday, May 25th. This is a boost from Johnson & Johnson's previous quarterly dividend of $0.80. View Johnson & Johnson's Dividend History.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) announced its earnings results on Tuesday, April, 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.77 by $0.06. The business had revenue of $17.77 billion for the quarter, compared to the consensus estimate of $18.02 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The firm's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.68 earnings per share. View Johnson & Johnson's Earnings History.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017. View Earnings Estimates for Johnson & Johnson.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

17 brokerages have issued 12 month price targets for Johnson & Johnson's stock. Their forecasts range from $112.80 to $145.00. On average, they anticipate Johnson & Johnson's stock price to reach $130.99 in the next twelve months. View Analyst Ratings for Johnson & Johnson.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
  • 2. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues.  While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
  • 3. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Who are some of Johnson & Johnson's key competitors?

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the folowing people:

  • Alex Gorsky, Chairman of the Board, Chief Executive Officer
  • Dominic J. Caruso, Chief Financial Officer, Executive Vice President
  • Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President
  • Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer
  • Michael H. Ullmann, Executive Vice President, General Counsel
  • Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals
  • Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer
  • Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman
  • Joseph Wolk, Vice President - Investor Relations
  • Anne M. Mulcahy, Lead Independent Director

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.28%), BlackRock Inc. (6.26%), State Street Corp (5.95%), State Farm Mutual Automobile Insurance Co. (1.40%), Bank of New York Mellon Corp (1.38%) and Wellington Management Group LLP (1.23%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nordea Investment Management AB, Pioneer Investment Management Inc., Boston Partners, Parametric Portfolio Associates LLC, Wellington Management Group LLP, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Paulus Stoffels and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Swiss National Bank, Alliancebernstein L.P. and Karp Capital Management Corp. View Insider Buying and Selling for Johnson & Johnson.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of Johnson & Johnson stock can currently be purchased for approximately $133.82.

MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  414 (Vote Outperform)
Underperform Votes:  501 (Vote Underperform)
Total Votes:  915
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 10 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $130.99 (2.12% downside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017Jefferies Group LLCReiterated RatingHold$140.00MediumView Rating Details
6/15/2017Royal Bank Of CanadaReiterated RatingBuy$128.00MediumView Rating Details
6/13/2017Cowen and CompanyReiterated RatingOutperform$143.00LowView Rating Details
6/2/2017BMO Capital MarketsReiterated RatingBuy$132.00LowView Rating Details
5/21/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/19/2017Morgan StanleyReiterated RatingEqual Weight$130.00 -> $135.00LowView Rating Details
5/18/2017Stifel NicolausReiterated RatingHold -> Hold$124.00 -> $128.00LowView Rating Details
5/15/2017J P Morgan Chase & CoUpgradeNeutral -> Overweight$123.64 -> $140.00HighView Rating Details
4/17/2017Barclays PLCReiterated RatingEqual Weight$125.00 -> $130.00LowView Rating Details
1/26/2017Wells Fargo & CompanyDowngradeOutperform -> Market Perform$112.28 -> $112.80N/AView Rating Details
1/25/2017Goldman Sachs Group, Inc. (The)Lower Price TargetNeutral$120.00 -> $115.00N/AView Rating Details
12/20/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
11/28/2016Bank of America CorporationReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00N/AView Rating Details
9/11/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 -> $106.00N/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00N/AView Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00N/AView Rating Details
(Data available from 6/29/2015 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.79
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20171$1.86$1.86$1.86
Q3 20171$1.80$1.80$1.80
Q4 20171$1.59$1.59$1.59
Q1 20181$1.98$1.98$1.98
Q2 20181$2.04$2.04$2.04
Q3 20181$1.99$1.99$1.99
Q4 20181$1.78$1.78$1.78
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Most Recent Dividend:6/13/2017
Annual Dividend:$3.36
Dividend Yield:2.51%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:56.47% (Trailing 12 Months of Earnings)
47.32% (Based on This Year's Estimates)
43.86% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 66.03%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
DateHeadline logoPfizer’s Valuation as of June 22, 2017 - June 27 at 6:15 PM logoJ&J CEO Gorsky Says U.S. Tax Reform Is Essential - June 26 at 7:56 PM logoJ&J CEO Gorsky Says Health Care Needs 10-20 Years of Work - June 26 at 7:56 PM logoJ&J CEO Gorsky Says Health Care Labor Market Is Tight - June 26 at 7:56 PM logoThis ‘classic’ Dow stock has come too far, too fast: Technician - June 26 at 7:56 PM logoJohnson & Johnson: The Better Activist Investor Bet - June 25 at 6:51 PM logoTrump’s adds NY Jets owner to diplomatic roster - June 25 at 6:51 PM logoHow Alphabet’s YouTube’s Ad Boycotters Fared - June 23 at 6:28 PM logoA New ETF For Low Vol ETFs - June 23 at 6:28 PM logoEx-DHS Secretary Jeh Johnson defends Obama handling of Russian meddling - June 22 at 12:54 PM logoJohnson & Johnson Releases 2016 Health for Humanity Report - June 22 at 12:54 PM logoJohnson & Johnson seeks to have Missouri talc suits dismissed - June 22 at 12:54 PM logo3 Perfect Stocks for Retirees in Their 70s to Consider Buying - June 22 at 12:54 PM logoHere's Why Geron (GERN) is a Good Stock to Invest in Now - June 22 at 12:53 PM logoMarkets Right Now: After early stumble, stocks drift higher - June 22 at 12:53 PM logoUnitedHealth, HCA, Merck Rally As Senate TrumpCare Bill Pares Near-Term Cuts - June 22 at 12:53 PM logoJohnson & Johnson (JNJ) Expected to Post Quarterly Sales of $18.89 Billion - June 22 at 10:24 AM logoMajor Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling - June 21 at 3:49 PM logo[$$] Missouri Files Its Own Suit Against Opioid-Painkiller Producers - June 21 at 3:49 PM logo[$$] J&J Seeking Dismissal of Talc Lawsuits in Missouri - June 21 at 3:49 PM logoDems Roast Trump for Leaving Medicare Out of Drug Price Order - June 21 at 3:49 PM logoTraders Buy Large Volume of Johnson & Johnson Put Options (JNJ) - June 21 at 7:14 AM logoUS Supreme Court ruling threatens massive talc litigation against J&J - Reuters - June 21 at 5:01 AM logoMistrial declared in talc suit following Supreme Court ruling - June 20 at 6:58 PM logoJ&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study - June 20 at 6:58 PM logoETFs with exposure to Johnson & Johnson : June 20, 2017 - June 20 at 6:58 PM logoJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results - June 20 at 6:58 PM logoFive classic Dow stocks are surging - June 20 at 6:58 PM logoA Short-Term Dip Is a Great Time to Consider Buying These Long-Term Stocks - June 20 at 6:58 PM logoWhy Pomalyst Could See Significant Revenue Growth in 2017 - June 20 at 6:58 PM logoJohnson & Johnson (JNJ) Expected to Announce Earnings of $1.79 Per Share - June 20 at 4:10 PM logoSupreme Court ruling results in talc lawsuit mistrial - June 19 at 5:48 PM logoJust 10 stocks are having an incredible impact on the market this year - June 19 at 5:03 PM logoFeatured Company News - J&J Completes Actelion Acquisition - June 19 at 12:12 PM logoJ&J Immunotherapy Darzalex Ok'd for Expanded Combination Use - June 19 at 12:12 PM logoAbbVie (ABBV) Stock Hits 52-Week High: More Room to Run? - June 19 at 12:12 PM logoJohnson & Johnson :JNJ-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017 - June 19 at 12:12 PM logo5 Reasons the Boring Parts of Johnson & Johnson's Business Should Generate Excitement - June 18 at 9:09 AM logo5 Reasons the Boring Parts of Johnson & Johnson's Business Should Generate Excitement - June 18 at 7:55 AM logoJohnson & Johnson (JNJ) Upgraded at BidaskClub - June 17 at 5:26 PM logoJohnson & Johnson's (JNJ) Management Presents at Goldman Sachs 38th Annual Global Healthcare Conference (Transcript) - June 17 at 12:02 AM logoJohnson & Johnson (JNJ) Completes Acquisition of Actelion - June 16 at 6:58 PM logoFeatured Company News - Johnson & Johnson Announces Flu Drug Update; Pimodivir Succeeds Mid-Stage Trial - June 16 at 6:58 PM logoPharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused - June 16 at 6:58 PM logoJohnson & Johnson's (JNJ) Hold Rating Reiterated at Jefferies Group LLC - June 16 at 8:10 AM logoJohnson & Johnson Completes Acquisition of Actelion - June 16 at 6:57 AM logoJohnson & Johnson Closes Acquisition Of Actelion - June 16 at 6:57 AM logoJohnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch - June 16 at 6:57 AM logoJohnson & Johnson Announces Completion of Acquisition of Actelion - June 16 at 6:57 AM logoJohnson & Johnson's (JNJ) "Buy" Rating Reaffirmed at Royal Bank Of Canada - June 15 at 9:26 PM



Johnson & Johnson (JNJ) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by Staff